- Title:
Schedule One - EDX Medical Group PLC - Time:
07:30:00 - Date:
13 Apr 2026 - Category:
Capital structure - ID:
0545A
⌘K
Loading...
|
ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES") |
|
|
|
COMPANY NAME: |
|
EDX Medical Group PLC ("the Company or EDX Medical")
|
|
COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TR ADING ADDRESS (INCLUDING POSTCODES): |
|
211 Cambridge Science Park Milton Road Cambridge Cambs England CB4 0WA
|
|
COUNTRY OF INCORPORATION: |
|
Incorporated in England and Wales
|
|
COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26: |
|
https://edxmedical.co.uk/aim-rule-26/
|
|
COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY. IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED: |
|
EDX Medical's main country of operation is the United Kingdom. It develops, validates and commercializes innovative digital diagnostic products and services, generating valuable biological insights that enable cost effective and timely delivery of personalised treatment for cancer, heart disease and infectious diseases.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to improve cost effectively the detection and characterisation of disease. The Directors believe that early disease detection and biologically-based personal treatment optimisation is the most impactful way of improving patient outcomes, improving survival and lowering the cost of healthcare globally.
EDX Medical provides healthcare professionals, providers and payors with access to a portfolio of clinical diagnostics products and services that the Directors believe represent leading technologies. The Company operates a molecular biology and diagnostics laboratory in Cambridge, UK, providing testing services accredited to ISO 15189(2022) by the United Kingdom Accreditation Service (UKAS) and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, which is recognised as a world leader in supplying life sciences solutions and services.
|
|
DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares): |
|
411,844,583 ordinary shares of £0.01 each
|
|
CAPITAL TO BE RAISED ON ADMISSION (AND/OR SECONDARY OFFERING) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION: |
|
None
£44.28m
|
|
PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION: |
|
39.36%
|
|
DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE ADMITTED OR TRADED: |
|
The ordinary shares are currently admitted to trading on the Apex Segment of Aquis Stock Exchange ("Aquis"). It is expected that trading of the ordinary shares on Aquis will be cancelled with effect from admission to AIM
|
|
THE COMPANY HAS APPLIED FOR THE VOLUNTARY CARBON MARKET DESIGNATION (Y/N) |
|
No
|
|
FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known): |
|
Jason Christopher Holt, Non-Executive Chair Martin Charles Walton, Deputy Chair Dr. Michael ("Mike") Hudson, Chief Executive Officer Professor Sir Christopher ("Chris") Thomas Evans, OBE, Chief Science Officer Professor Trevor Mervyn Jones, Non-executive Director
|
|
FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known): |
|
All holdings are the same both pre and post Admission
Professor Sir Christopher ("Chris") Evans - 136,161,523 - 33.06% Bridgemere Securities - 38,970,000 - 9.46% West Coast Capital - 31,439,582 - 7.63% Countrywide Development Limited - 24,166,667 - 5.87% Dr. Michael ("Mike") Hudson - 20,650,000 - 5.01%
|
|
NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES: |
|
None
|
|
(i) ANTICIPATED ACCOUNTING REFERENCE DATE (ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information) (iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19: |
|
(i) 31 March (ii) Unaudited interim results to 30 September 2025 (iii) By 30 September 2026, 31 December 2026 and 30 September 2027
|
|
EXPECTED ADMISSION DATE: |
|
13 May 2026
|
|
NAME AND ADDRESS OF NOMINATED ADVISER: |
|
Canaccord Genuity Limited 88 Wood Street London EC2V 7QR
|
|
NAME AND ADDRESS OF BROKER: |
|
Canaccord Genuity Limited 88 Wood Street London EC2V 7QR
|
|
OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: |
|
N/A
|
|
THE CORPORATE GOVERNANCE CODE THE APPLICANT HAS DECIDED TO APPLY |
|
Quoted Companies Alliance Corporate Governance Code
|
|
DATE OF NOTIFICATION: |
|
13 April 2026
|
|
NEW/ UPDATE: |
|
NEW |
|
QUOTED APPLICANTS MUST ALSO COMPLETE THE FOLLOWING: |
|
|
|
THE NAME OF THE AIM DESIGNATED MARKET UPON WHICH THE APPLICANT'S SECURITIES HAVE BEEN TRADED: |
|
Apex Segment of Aquis Stock Exchange
|
|
THE DATE FROM WHICH THE APPLICANT'S SECURITIES HAVE BEEN SO TRADED: |
|
29th April 2024
|
|
CONFIRMATION THAT, FOLLOWING DUE AND CAREFUL ENQUIRY, THE APPLICANT HAS ADHERED TO ANY LEGAL AND REGULATORY REQUIREMENTS INVOLVED IN HAVING ITS SECURITIES TRADED UPON SUCH A MARKET OR DETAILS OF WHERE THERE HAS BEEN ANY BREACH: |
|
This is confirmed
|
|
AN ADDRESS OR WEB-SITE ADDRESS WHERE ANY DOCUMENTS OR ANNOUNCEMENTS WHICH THE APPLICANT HAS MADE PUBLIC OVER THE LAST TWO YEARS (IN CONSEQUENCE OF HAVING ITS SECURITIES SO TRADED) ARE AVAILABLE: |
|
|
|
DETAILS OF THE APPLICANT'S STRATEGY FOLLOWING ADMISSION INCLUDING, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING STRATEGY: |
|
EDX Medical is a growing digital diagnostics business, specialised in providing diagnostic tests for clinical use which reveal critical information to help healthcare professionals and their patients improve clinical decision-making and achieve better outcomes. In order to compete successfully in the clinical diagnostics sector, EDX Medical has established core competencies in the identification, development and validation of tests and associated secure data analytical reporting to imminent new UK and European regulatory standards. The board believes that these key skills make EDX Medical the provider of choice for clients and a strong marketing and distribution partner for collaborators.
EDX Medical provides healthcare professionals, providers and payors with access to a portfolio of proprietary diagnostic tests across both 'Laboratory Assays' and 'Point of Care' testing - two major segments of the growing global clinical diagnostics market, addressing three disease areas of great global health and economic impact - cancer, cardiovascular and infectious diseases. Both product lines are considered to be capable of addressing large global public and private sector markets for improved healthcare testing and secure digital reporting.
The Laboratory Assay portfolio includes market-ready advanced cancer tests from world-leading partners under exclusive distribution arrangements contributing initial revenues, alongside a growing number of products developed by EDX Medical in partnership with Thermo Fisher, with whom EDX Medical has a strategic collaboration. EDX Medical is establishing initial revenues and product validation in the UK. It is intended that optimised EDX Medical products will then be made into kits, validated and submitted for CE- IVDR regulatory approval, for sale to laboratories in the public and private healthcare sector across Europe, which the Directors believe will create a highly scaleable business model.
The 'Point of Care' test range is based on the patent-pending multiplex test platform acquired with Hutano Diagnostics Ltd, which provides highly sensitive and quantitative data for multiple key biomarkers in a handheld 20-minute test device, with data reporting via mobile phone. Initial applications currently in validation include PoC tests for sepsis and prostate cancer.
· Specialist: Focussed on Areas of Significant Global Impact: cancer, cardiovascular and infectious diseases,
· Building a Portfolio of Unique and Clinically Validated Assays: 'best in class' tests for genetic risk, early disease detection and characterisation.
· Early Revenues and Market Access via Distribution Partnerships: exclusive partnerships with Caris Life Sciences and with Curesponse Ltd.
· Strong Pipeline via Collaboration with Thermo Fisher proprietary assays addressing global needs co-developed based on in-licensed intellectual property from Oxford and Cambridge Universities and others.
· Pioneering Multiplex 'Point of Care' Test Platform, Quantitative data on multiple biomarkers with digital reporting via mobile phone for sepsis and prostate cancers in validation.
· Commercially Scalable Clear commercial growth strategy minimises technical and commercial risks, with potential for European expansion in the clinical diagnostics market.
|
|
A DESCRIPTION OF ANY SIGNIFICANT CHANGE IN FINANCIAL OR TRADING POSITION OF THE APPLICANT, WHICH HAS OCCURRED SINCE THE END OF THE LAST FINANCIAL PERIOD FOR WHICH AUDITED STATEMENTS HAVE BEEN PUBLISHED: |
|
Save as disclosed below there have been no significant changes in the financial or trading position of the Company since 30 September 2025 being the balance sheet date to which the interims accounts of the Company were made up:
On 23 October 2025 the Company issued 14,285,713 new Ordinary Shares at a price of 14p each to raise £2.0m and entered in to a new convertible loan note facility which is available until 9 October 2029 with Sir Chris Evans under which a total of £2.0m can be drawn subject to certain conditions. No drawings have yet been made on this facility.
On 20 February 2026 the Company issued 24,999,999 new Ordinary Shares at a price of 14p to raise proceeds of £3.5m
On 13 April 2026 the Company announced a term loan facility of £3.71m from Sir Chris Evans to meet the working capital needs of the company, in conjunction with the convertible loan note referred to above, for the period to 31 December 2027
|
|
A STATEMENT THAT THE DIRECTORS OF THE APPLICANT HAVE NO REASON TO BELIEVE THAT THE WORKING CAPITAL AVAILABLE TO IT OR ITS GROUP WILL BE INSUFFICIENT FOR AT LEAST TWELVE MONTHS FROM THE DATE OF ITS ADMISSION: |
|
The Directors have no reason to believe that the working capital available to the Company will be insufficient for at least the 12 months from Admission
|
|
DETAILS OF ANY LOCK-IN ARRANGEMENTS PURSUANT TO RULE 7 OF THE AIM RULES: |
|
None
|
|
A BRIEF DESCRIPTION OF THE ARRANGEMENTS FOR SETTLING THE APPLICANT'S SECURITIES: |
|
Settlement will continue to be through the Euroclear System for dealings in Ordinary Shares held in uncertificated form. Ordinary Shares can also be dealt with in certificated form.
|
|
A WEBSITE ADDRESS DETAILING THE RIGHTS ATTACHING TO THE APPLICANT'S SECURITIES: |
|
Articles-of-Association-2025-12-08.pdf and TEXAS Admission Document Final 261022
|
|
INFORMATION EQUIVALENT TO THAT REQUIRED FOR AN ADMISSION DOCUMENT WHICH IS NOT CURRENTLY PUBLIC: |
|
The announcement released on 13 April 2026 by EDX entitled "Proposed cancellation of Ordinary Shares from the Aquis Stock Exchange and proposed application for admission to trading on AIM" contains, inter alia, information equivalent to that required for an Admission Document and which is not already public.
A copy of the announcement is available on the Company's website: RNS - EDX Medical
|
|
A WEBSITE ADDRESS OF A PAGE CONTAINING THE APPLICANT'S LATEST ANNUAL REPORT AND ACCOUNTS WHICH MUST HAVE A FINANCIAL YEAR END NOT MORE THEN NINE MONTHS PRIOR TO ADMISSION AND INTERIM RESULTS WHERE APPLICABLE. THE ACCOUNTS MUST BE PREPARED IN ACCORDANCE WITH ACCOUNTING STANDARDS PERMISSIBLE UNDER AIM RULE 19: |
|
Corporate Documents - EDX Medical
|
|
THE NUMBER OF EACH CLASS OF SECURITIES HELD IN TREASURY: |
|
NONE
|
Schedule One - EDX Medical Group PLC07:30:0013 Apr 2026Capital structure0545A